Chiesi inaugurates the expansion of its industrial site in La Chaussée-Saint-Victor, a strategic investment towards sustainable respiratory options for patients
04 Novembre 2025
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs
06 Ottobre 2025
Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized Metered-Dose Inhalers (pMDIs), Paving the Way for Regulatory Submissions
26 Settembre 2025
Chiesi Group accelerates sustainable growth in H1 2025, delivering strong financial results and reaffirming commitment to Shared Value
16 Settembre 2025
Chiesi Global Rare Diseases receives Swissmedic approval for FILSUVEZ® topical gel for the treatment of epidermolysis bullosa
11 Agosto 2025
Chiesi Group and Serna Bio announce strategic collaboration to discover and develop RNA-targeted small molecules for respiratory diseases
24 Luglio 2025
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
16 Aprile 2025
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
